|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Primary Brain Cancer
Datamonitor, July 2007, Pages: 84
Introduction
Incidence of primary brain cancer across the seven major markets in 2007 is estimated to be 47,000. Over half of these cases will be glioblastoma multiforme, for which survival prospects are dismal. The median survival for this group of patients is 1.2 years and only 27% of patients are alive after two years. The level of unmet need is therefore high in this disease.
Scope
Incidence, diagnosis and treatment of primary brain cancer, including treatment regimens by stage and ongoing controversies Unmet needs, emerging trends and commercial incentives in primary brain cancer Examination of pipeline activity and potential future opportunities for drug developers Stakeholder opinions and interview transcripts based on qualitative interviews with six opinion leaders from the US and Europe
Highlights
The standard set by drugs that have been approved for primary brain cancer is low; therefore drugs only need to demonstrate relatively modest improvements in survival to be adopted by physicians. A substantial opportunity also exists for a second-line chemotherapy to enter the primary brain cancer market. Several molecular markers have been associated with glioma. It is possible that these markers could significantly affect treatment patterns, resulting in a stratified glioma market. Targeted therapies could be reserved solely for patients whose molecular profile indicates that they will benefit from such drugs. The potential of Phase III pipeline drugs is limited by factors such as low efficacy and complicated delivery methods. Of the drugs in the Phase II pipeline for glioma, targeted therapies show most potential. In particular, angiogenesis inhibitors have considerable commercial potential because they may reduce the co-morbidity edema.
Reasons to Purchase
Identify the limitations of current therapy available to primary brain cancer patients and the potential of future therapy Understand current epidemiological trends in primary brain cancer and ongoing treatment controversies Assess the opportunities for innovative targeted therapies in primary brain cancer, particularly in recurrent disease
Customers who bought this item also bought
Glioblastoma Review - Temodar partnering pipeline drugs
Glioblastoma - Is There life After Temodar?
Stakeholder Opinions: Primary Brain Cancer - Temozolomide Turns Heads
Prospects for the Phase III Bapineuzumab Trial
Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs
Pipeline Insight: Molecular Targeted Cancer Therapies - More Pipeline Activity, Less Product Differentiation
Stakeholder Opinions: Bladder Cancer - New Drugs Needed to Challenge Ineffective 20-year Old drugs
Stakeholder Opinions: Esophageal Cancer Treatment Paradigms Need Revolution Not Evolution
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies - More Drugs on the Market, More Targets in the Pipeline
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma - Limited R&D Activity Provides Opportunity for Early-Phase Pipeline Drugs
Niche Cancers 2001: Glioblastoma
Cancer Therapies - Global Strategic Business Report
|
|
|
|
